Improved 3-year survival rates for glioblastoma multiforme are associated with trends in treatment: analysis of the national cancer database from 2004 to 2013

• Published in: Journal of neuro-oncology 2020-05, Vol.148 (1), p.69-79
• Main Authors: Zreik, Jad, Moinuddin, F. M., Yolcu, Yagiz U., Alvi, Mohammed Ali, Chaichana, Kaisorn L., Quinones-Hinojosa, Alfredo, Bydon, Mohamad
• Format: Article
• Language: English
• Subjects: Aged; Brain cancer; Brain Neoplasms - diagnosis; Brain Neoplasms - mortality; Brain Neoplasms - therapy; Clinical Study; Databases, Factual; Female; Glioblastoma; Glioblastoma - diagnosis; Glioblastoma - mortality; Glioblastoma - therapy; Humans; Male; Malignancy; Medical prognosis; Medicine; Medicine & Public Health; Methylation; Middle Aged; Neurology; Oncology; Patients; Survival; Survival Analysis; Survival Rate; Treatment Outcome; Trends
• ISSN: 0167-594X; 1573-7373
• DOI: 10.1007/s11060-020-03469-w

Purpose Glioblastoma multiforme (GBM) is a common and aggressive malignancy associated with poor prognosis. Characteristics and treatment of long-term survivors are of particular interest in efforts to improve outcomes. Therefore, the objective of this study was to examine trends and prognostic factors for 3-year survival from a national database. Methods The National Cancer Database (NCDB) was queried for patients diagnosed with cranial GBM from 2004 to 2013 and with 3-year follow-up. Trends in 3-year and overall survival, patient characteristics, tumor properties, and treatment modalities were examined. Multivariable logistic regression was utilized to investigate the association of these factors with 3-year survival. Predictor importance analysis was conducted using a metric defined as Wald χ 2 penalized by degrees of freedom. Results A total of 88,919 GBM patients with 3-year follow-up were identified. Overall, 8757 (9.8%) patients survived ≥ 3 years. Three-year survival significantly improved from 8.0 to 10.5% (p